vs
Side-by-side financial comparison of Inuvo, Inc. (INUV) and ROCKWELL MEDICAL, INC. (RMTI). Click either name above to swap in a different company.
ROCKWELL MEDICAL, INC. is the larger business by last-quarter revenue ($18.3M vs $14.3M, roughly 1.3× Inuvo, Inc.). ROCKWELL MEDICAL, INC. runs the higher net margin — -3.0% vs -4.2%, a 1.1% gap on every dollar of revenue. On growth, ROCKWELL MEDICAL, INC. posted the faster year-over-year revenue change (-25.6% vs -45.6%). ROCKWELL MEDICAL, INC. produced more free cash flow last quarter ($2.2M vs $-339.9K). Over the past eight quarters, Inuvo, Inc.'s revenue compounded faster (-8.5% CAGR vs -10.1%).
Inuvo, Inc. is a digital marketing technology firm that develops AI-powered advertising solutions. It offers intent-based audience targeting, performance marketing, and brand awareness services for retail, finance, and consumer goods clients, mainly operating across the North American market.
Rockwell Medical Inc. is a publicly traded pharmaceutical company based in Wixom, Michigan and founded in 1996 that focuses on development and commercialization of treatments against diseases such as end-stage renal disease (ESRD) and chronic kidney disease (CKD).
INUV vs RMTI — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $14.3M | $18.3M |
| Net Profit | $-593.9K | $-554.0K |
| Gross Margin | 66.4% | 21.1% |
| Operating Margin | -8.5% | -2.2% |
| Net Margin | -4.2% | -3.0% |
| Revenue YoY | -45.6% | -25.6% |
| Net Profit YoY | -520.2% | 26.7% |
| EPS (diluted) | — | $-0.01 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $14.3M | $18.3M | ||
| Q3 25 | $22.6M | $15.9M | ||
| Q2 25 | $22.7M | $16.1M | ||
| Q1 25 | $26.7M | $18.9M | ||
| Q4 24 | $26.2M | $24.7M | ||
| Q3 24 | $22.4M | $28.3M | ||
| Q2 24 | $18.2M | $25.8M | ||
| Q1 24 | $17.0M | $22.7M |
| Q4 25 | $-593.9K | $-554.0K | ||
| Q3 25 | $-1.7M | $-1.8M | ||
| Q2 25 | $-1.5M | $-1.5M | ||
| Q1 25 | $-1.3M | $-1.5M | ||
| Q4 24 | $141.3K | $-756.0K | ||
| Q3 24 | $-2.0M | $1.7M | ||
| Q2 24 | $-1.7M | $343.0K | ||
| Q1 24 | $-2.1M | $-1.7M |
| Q4 25 | 66.4% | 21.1% | ||
| Q3 25 | 73.4% | 14.3% | ||
| Q2 25 | 75.4% | 15.6% | ||
| Q1 25 | 79.0% | 16.1% | ||
| Q4 24 | 83.1% | 14.7% | ||
| Q3 24 | 88.4% | 22.0% | ||
| Q2 24 | 84.0% | 17.6% | ||
| Q1 24 | 87.7% | 13.5% |
| Q4 25 | -8.5% | -2.2% | ||
| Q3 25 | -7.4% | -9.9% | ||
| Q2 25 | -9.0% | -8.4% | ||
| Q1 25 | -6.6% | -7.2% | ||
| Q4 24 | 0.8% | -2.1% | ||
| Q3 24 | -8.7% | 6.8% | ||
| Q2 24 | -9.3% | 2.0% | ||
| Q1 24 | -12.3% | -5.8% |
| Q4 25 | -4.2% | -3.0% | ||
| Q3 25 | -7.7% | -11.0% | ||
| Q2 25 | -6.6% | -9.3% | ||
| Q1 25 | -4.7% | -8.0% | ||
| Q4 24 | 0.5% | -3.1% | ||
| Q3 24 | -9.1% | 5.9% | ||
| Q2 24 | -9.6% | 1.3% | ||
| Q1 24 | -12.4% | -7.6% |
| Q4 25 | — | $-0.01 | ||
| Q3 25 | $-0.12 | $-0.05 | ||
| Q2 25 | — | $-0.05 | ||
| Q1 25 | $-0.01 | $-0.04 | ||
| Q4 24 | $0.14 | $-0.02 | ||
| Q3 24 | $-0.15 | $0.04 | ||
| Q2 24 | $-0.01 | $0.01 | ||
| Q1 24 | $-0.02 | $-0.06 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $10.7M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $10.0M | $37.0M |
| Total Assets | $24.9M | $57.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $10.7M | ||
| Q3 25 | — | $13.6M | ||
| Q2 25 | — | $12.5M | ||
| Q1 25 | — | $11.4M | ||
| Q4 24 | — | $15.7M | ||
| Q3 24 | — | $12.3M | ||
| Q2 24 | $2.0M | $11.9M | ||
| Q1 24 | $2.0M | $6.6M |
| Q4 25 | $10.0M | $37.0M | ||
| Q3 25 | $10.4M | $37.0M | ||
| Q2 25 | $12.1M | $30.4M | ||
| Q1 25 | $13.4M | $31.5M | ||
| Q4 24 | $13.5M | $32.6M | ||
| Q3 24 | $12.4M | $29.1M | ||
| Q2 24 | $13.5M | $23.5M | ||
| Q1 24 | $15.1M | $20.6M |
| Q4 25 | $24.9M | $57.1M | ||
| Q3 25 | $29.9M | $57.5M | ||
| Q2 25 | $28.7M | $52.6M | ||
| Q1 25 | $31.7M | $54.0M | ||
| Q4 24 | $32.2M | $59.2M | ||
| Q3 24 | $29.0M | $57.1M | ||
| Q2 24 | $28.5M | $53.0M | ||
| Q1 24 | $29.8M | $50.7M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $21.0K | $2.3M |
| Free Cash FlowOCF − Capex | $-339.9K | $2.2M |
| FCF MarginFCF / Revenue | -2.4% | 12.0% |
| Capex IntensityCapex / Revenue | 2.5% | 0.5% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-3.4M | $-1.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $21.0K | $2.3M | ||
| Q3 25 | $-1.6M | $-1.3M | ||
| Q2 25 | $143.7K | $1.8M | ||
| Q1 25 | $-366.9K | $-3.5M | ||
| Q4 24 | $329.9K | $865.0K | ||
| Q3 24 | $1.1M | $4.3M | ||
| Q2 24 | $195.4K | $1.4M | ||
| Q1 24 | $-1.4M | $-2.4M |
| Q4 25 | $-339.9K | $2.2M | ||
| Q3 25 | $-2.0M | $-1.5M | ||
| Q2 25 | $-263.1K | $1.7M | ||
| Q1 25 | $-818.6K | $-3.5M | ||
| Q4 24 | $-117.7K | $470.0K | ||
| Q3 24 | $584.0K | $4.1M | ||
| Q2 24 | $-266.3K | $1.2M | ||
| Q1 24 | $-1.8M | $-2.5M |
| Q4 25 | -2.4% | 12.0% | ||
| Q3 25 | -8.7% | -9.6% | ||
| Q2 25 | -1.2% | 10.5% | ||
| Q1 25 | -3.1% | -18.8% | ||
| Q4 24 | -0.4% | 1.9% | ||
| Q3 24 | 2.6% | 14.4% | ||
| Q2 24 | -1.5% | 4.5% | ||
| Q1 24 | -10.7% | -11.1% |
| Q4 25 | 2.5% | 0.5% | ||
| Q3 25 | 1.7% | 1.4% | ||
| Q2 25 | 1.8% | 1.0% | ||
| Q1 25 | 1.7% | 0.3% | ||
| Q4 24 | 1.7% | 1.6% | ||
| Q3 24 | 2.1% | 0.7% | ||
| Q2 24 | 2.5% | 1.1% | ||
| Q1 24 | 2.8% | 0.6% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 2.33× | — | ||
| Q3 24 | — | 2.57× | ||
| Q2 24 | — | 4.20× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
INUV
Segment breakdown not available.
RMTI
| US | $15.9M | 87% |
| Non Us | $2.4M | 13% |
